# EDGAR Filing Document

**Accession Number:** 0001958777
**File Stem:** 0001193125-26-149654
**Filing Date:** 2026-4
**Character Count:** 5556
**Document Hash:** f79a1aebf332b7541bb888ec8e45a8d6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-149654.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001193125-26-149654

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260403

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FibroBiologics, Inc.
- **CENTRAL INDEX KEY:** 0001958777
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863329066
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41934
- **FILM NUMBER:** 26851756

**BUSINESS ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054
- **BUSINESS PHONE:** 281-671-5150

**MAIL ADDRESS:**
- **STREET 1:** 9350 KIRBY DRIVE
- **STREET 2:** SUITE 300
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77054

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FibroBiologics Inc.
- **DATE OF NAME CHANGE:** 20221216

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** April 03, 2026<br>

------

FibroBiologics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-41934 | 86-3329066 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 9350 Kirby Drive, Suite 300 |  |  |
| Houston**,** Texas |  | 77054 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 281 671-5150<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.00001 par value<br> FBLG | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 1.01 Entry into a Material Definitive Agreement.
On April 3, 2026, FibroBiologics, Inc. (the "Company") entered into a Sublease Buyout Agreement (the "Lease Termination Agreement") with United Fire & Casualty Co. (doing business as United Fire Group) (the "Sublandlord") to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 ("Sublease"), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598. The Lease Termination Agreement terminated the Sublease effective April 2, 2026, successfully concluding the Sublease well ahead of its original expiration date of November 30, 2027. The Company resolved its remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent payments.

This strategic consolidation follows the Company's 2025 opening of its state-of-the-art laboratory facility, encompassing over 10,000 square feet of dedicated lab and office space. By eliminating redundant office costs approximately 18 months ahead of schedule, the Company strengthens its operational efficiency and redirects resources toward its core mission of advancing fibroblast-based therapeutics.

**Item 8.01 Other Events.**

The new address of the Company's principal executive offices is 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

## Item 9.01 Financial Statements and Exhibits.
Exhibit 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | FibroBiologics, Inc. |
| Date: | Apri 9, 2026 | By:  | /s/ Pete O'Heeron |
|  |  |  | Name: Pete O'Heeron<br>Title: Chief Executive Officer |

---

------